Seagen Inc (SGEN)

Add to Watchlists
Create an Alert
Quickflows
156.31 +2.93  +1.91% NASDAQ Jun 18, 20:00 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All SGEN News

News

View All Events

Events

Date Type Description
07/30/2021 Earnings Results Q2 2021 Earnings Results
07/30/2021 16:30 EST Earnings Calls Q2 2021 Earnings Call
04/29/2021 Earnings Results Q1 2021 Earnings Results
04/29/2021 16:30 EST Earnings Calls Q1 2021 Earnings Call
02/11/2021 Earnings Results Q4 2020 Earnings Results
02/11/2021 16:30 EST Earnings Calls Q4 2020 Earnings Call
10/29/2020 16:30 EST Earnings Calls Q3 2020 Earnings Call
10/29/2020 Earnings Results Q3 2020 Earnings Results
07/30/2020 16:30 EST Earnings Calls Q2 2020 Earnings Call
07/30/2020 Earnings Results Q2 2020 Earnings Results
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 2.273B
Total Expenses (TTM) 1.686B
Net Income (TTM) 660.65M

Balance Sheet View Statement

Total Assets (Quarterly) 3.943B
Total Liabilities (Quarterly) 518.36M
Shareholders Equity (Quarterly) 3.425B

Cash Flow Statement View Statement

Cash from Operations (TTM) 800.30M
Cash from Investing (TTM) -1.520B
Cash from Financing (TTM) 844.11M

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Seagen (formerly Seattle Genetics) is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. Other approved products include Padcev (bladder cancer) and Tukysa (breast cancer). The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.
  • URL: https://www.seagen.com
  • Investor Relations URL: https://investor.seagen.com/
  • HQ State/Province: Washington
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Jul. 30, 2021
  • Last Earnings Release: Apr. 29, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 156.31
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
BBH VanEck Vectors Biotech ETF 4.11%
FBT First Trust NYSE Arca Biotech ETF 3.29%
DYN1581 Dynamic Power Global Growth Class Sr IP (USD) 2.78%
HQL Tekla Life Sciences Investors 2.65%
DYN1628 Dynamic Power American Growth Series IP (USD) 2.41%
BMEZ BlackRock Health Sciences Trust II 2.28%
IBB iShares Nasdaq Biotechnology ETF 2.21%
POAGX PRIMECAP Odyssey Aggressive Growth 2.10%
SHISX BlackRock Health Sciences Opps Svc 1.66%
HQH Tekla Healthcare Investors 1.61%
POGRX PRIMECAP Odyssey Growth 1.46%
VHCOX Vanguard Capital Opportunity Inv 1.36%

Comparables

Edit
CRIS Curis Inc
NBIX Neurocrine Biosciences Inc
NVAX Novavax Inc
XLRN Acceleron Pharma Inc
ALGN Align Technology Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.